Dynamics and function of distal regulatory elements during neurogenesis and neuroplasticity

Genome Research

Volumn 25, Issue 9, 2015, Pages 1309-1324

  Thakurela, Sudhir ^a   Sahu, Sanjeeb Kumar ^a   Garding, Angela ^a   Tiwari, Vijay K ^a  

^a INSTITUTE OF MOLECULAR BIOLOGY IMB   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

N METHYL DEXTRO ASPARTIC ACID RECEPTOR; TRANSCRIPTION FACTOR; TRANSCRIPTOME; CHROMATIN; HISTONE;

ANIMAL CELL; ARTICLE; CELL MATURATION; CHROMATIN; CONTROLLED STUDY; DYNAMICS; EMBRYO; ENHANCER REGION; EPIGENETICS; GENE CONTROL; GENETIC TRANSCRIPTION; GENOME; GENOMICS; MOUSE; NERVE CELL; NERVE CELL PLASTICITY; NERVOUS SYSTEM DEVELOPMENT; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; ANIMAL; ANTIBODY SPECIFICITY; CLUSTER ANALYSIS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETICS; HIGH THROUGHPUT SEQUENCING; METABOLISM; NUCLEAR REPROGRAMMING; PROCEDURES; REGULATORY SEQUENCE; SIGNAL TRANSDUCTION;

ANIMALS; CELLULAR REPROGRAMMING; CHROMATIN; CLUSTER ANALYSIS; EPIGENESIS, GENETIC; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENOMICS; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HISTONES; MICE; NEUROGENESIS; NEURONAL PLASTICITY; NEURONS; ORGAN SPECIFICITY; RECEPTORS, N-METHYL-D-ASPARTATE; REGULATORY ELEMENTS, TRANSCRIPTIONAL; REGULATORY SEQUENCES, NUCLEIC ACID; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC; TRANSCRIPTOME;

EID: 84940973203     PISSN: 10889051     EISSN: 15495469     Source Type: Journal    
DOI: 10.1101/gr.190926.115     Document Type: Article

References (76)

1. Ahmed I, Bose SK, Pavese N, Ramlackhansingh A, Turkheimer F, Hotton G, Hammers A, Brooks DJ. 2011. Glutamate NMDA receptor dysregulation in Parkinson's disease with dyskinesias. Brain 134(Pt 4): 979-986.
2. Andersson R, Gebhard C, Miguel-Escalada I, Hoof I, Bornholdt J, Boyd M, Chen Y, Zhao X, Schmidl C, Suzuki T, et al. 2014. An atlas of active enhancers across human cell types and tissues. Nature 507: 455-461.
3. Bell O, Tiwari VK, Thomä NH, Schübeler D. 2011. Determinants and dynamics of genome accessibility. Nat Rev Genet 12: 554-564.
4. Bibel M, Richter J, Schrenk K, Tucker KL, Staiger V, Korte M, Goetz M, Barde YA. 2004. Differentiation of mouse embryonic stem cells into a defined neuronal lineage. Nat Neurosci 7: 1003-1009.
5. Blanchet PJ, Papa SM, Metman LV, Mouradian MM, Chase TN. 1997. Modulation of levodopa-induced motor response complications by NMDA antagonists in Parkinson's disease. Neurosci Biobehav Rev 21: 447-453.
6. Bonn S, Zinzen RP, Girardot C, Gustafson EH, Perez-Gonzalez A, Delhomme N, Ghavi-Helm Y, Wilczyński B, Riddell A, Furlong EE. 2012. Tissue-specific analysis of chromatin state identifies temporal signatures of enhancer activity during embryonic development. Nat Genet 44: 148-156.
7. Borrelli E, Nestler EJ, Allis CD, Sassone-Corsi P. 2008. Decoding the epigenetic language of neuronal plasticity. Neuron 60: 961-974.
8. Bossy-Wetzel E, Schwarzenbacher R, Lipton SA. 2004. Molecular pathways to neurodegeneration. Nat Med 10(Suppl): S2-S9.
9. Bowers EM, Yan G, Mukherjee C, Orry A, Wang L, Holbert MA, Crump NT, Hazzalin CA, Liszczak G, Yuan H, et al. 2010. Virtual ligand screening of the p300/CBP histone acetyltransferase: identification of a selective small molecule inhibitor. Chem Biol 17: 471-482.
10. Chen Y, Wang Y, Modrusan Z, Sheng M, Kaminker JS. 2014. Regulation of neuronal gene expression and survival by basal NMDA receptor activity: A role for histone deacetylase 4. J Neurosci 34: 15327-15339.
11. Choi DW. 1988. Glutamate neurotoxicity and diseases of the nervous system. Neuron 1: 623-634.
12. Choi DW. 1992. Excitotoxic cell death. J Neurobiol 23: 1261-1276.
13. Connor SA, Wang YT. 2015. A place at the table: LTD as a mediator of memory genesis. Neuroscientist doi:10.1177/1073858415588498.
14. Coyle JT, Tsai G. 2004. NMDA receptor function, neuroplasticity, and the pathophysiology of schizophrenia. Int Rev Neurobiol 59: 491-515.
15. Creyghton MP, Cheng AW, Welstead GG, Kooistra T, Carey BW, Steine EJ, Hanna J, Lodato MA, Frampton GM, Sharp PA, et al. 2010. Histone H3K27ac separates active from poised enhancers and predicts developmental state. Proc Natl Acad Sci 107: 21931-21936.
16. Deisseroth K, Heist EK, Tsien RW. 1998. Translocation of calmodulin to the nucleus supports CREB phosphorylation in hippocampal neurons. Nature 392: 198-202.
17. Dekker J. 2012. CTCF and cohesin help neurons raise their self-awareness. Proc Natl Acad Sci 109: 8799-8800.
18. Doyle B, Fudenberg G, Imakaev M, Mirny LA. 2014. Chromatin loops as allosteric modulators of enhancer-promoter interactions. PLoS Comput Biol 10: E1003867.
19. Feng J, Fouse S, Fan G. 2007. Epigenetic regulation of neural gene expression and neuronal function. Pediatr Res 61(5 Pt 2): 58R-63R.
20. Giresi PG, Kim J, McDaniell RM, Iyer VR, Lieb JD. 2007. FAIRE (Formaldehyde-Assisted Isolation of Regulatory Elements) isolates active regulatory elements from human chromatin. Genome Res 17: 877-885.
21. Götz M, Huttner WB. 2005. The cell biology of neurogenesis. Nat Rev Mol Cell Biol 6: 777-788.
22. Hardingham GE, Bading H. 2003. The Yin and Yang of NMDA receptor signalling. Trends Neurosci 26: 81-89.
23. Hirayama T, Tarusawa E, Yoshimura Y, Galjart N, Yagi T. 2012. CTCF is required for neural development and stochastic expression of clustered Pcdh genes in neurons. Cell Rep 2: 345-357.
24. Hnisz D, Abraham BJ, Lee TI, Lau A, Saint-André V, Sigova AA, Hoke HA, Young RA. 2013. Super-enhancers in the control of cell identity and disease. Cell 155: 934-947.
25. Hu XL, Wang Y, Shen Q. 2012. Epigenetic control on cell fate choice in neural stem cells. Protein Cell 3: 278-290.
26. Huh GS, Boulanger LM, Du H, Riquelme PA, Brotz TM, Shatz CJ. 2000. Functional requirement for class I MHC in CNS development and plasticity. Science 290: 2155-2159.
27. Ikonomidou C, Qin Qin Y, Labruyere J, Olney JW. 1996. Motor neuron degeneration induced by excitotoxin agonists has features in common with those seen in the SOD-1 transgenic mouse model of amyotrophic lateral sclerosis. J Neuropathol Exp Neurol 55: 211-224.
28. Kalia LV, Kalia SK, Salter MW. 2008. NMDA receptors in clinical neurology: Excitatory times ahead. Lancet Neurol 7: 742-755.
29. Kandel ER. 2001. The molecular biology of memory storage: A dialogue between genes and synapses. Science 294: 1030-1038.
30. Kim TK, Hemberg M, Gray JM, Costa AM, Bear DM, Wu J, Harmin DA, Laptewicz M, Barbara-Haley K, Kuersten S, et al. 2010. Widespread transcription at neuronal activity-regulated enhancers. Nature 465: 182-187.
31. Koenig O. 1995. [Perception and memory: illustration of an approach of the study of visual mechanisms in cognitive neuroscience]. Rev Neurol 151: 451-456.
32. Koohy H, Down TA, Hubbard TJ. 2013. Chromatin accessibility data sets show bias due to sequence specificity of the DNase I enzyme. PLoS One 8: E69853.
33. Lee S, Cuvillier JM, Lee B, Shen R, Lee JW, Lee SK. 2012. Fusion protein Isl1-Lhx3 specifies motor neuron fate by inducing motor neuron genes and concomitantly suppressing the interneuron programs. Proc Natl Acad Sci 109: 3383-3388.
34. Lee S, Shen R, Cho HH, Kwon RJ, Seo SY, Lee JW, Lee SK. 2013. STAT3 promotes motor neuron differentiation by collaborating with motor neuron-specific LIM complex. Proc Natl Acad Sci 110: 11445-11450.
35. Lienert F, Mohn F, Tiwari VK, Baubec T, Roloff TC, Gaidatzis D, Stadler MB, Schübeler D. 2011. Genomic prevalence of heterochromatic H3K9me2 and transcription do not discriminate pluripotent from terminally differentiated cells. PLoS Genet 7: E1002090.
36. Lipton SA, Rosenberg PA. 1994. Excitatory amino acids as a final common pathway for neurologic disorders. N Engl J Med 330: 613-622.
37. Lister R, Mukamel EA, Nery JR, Urich M, Puddifoot CA, Johnson ND, Lucero J, Huang Y, Dwork AJ, Schultz MD, et al. 2013. Global epigenomic reconfiguration during mammalian brain development. Science 341: 1237905.
38. Lopez-Atalaya JP, Barco A. 2014. Can changes in histone acetylation contribute to memory formation? Trends Genet 30: 529-539.
39. Maeda M, Johnson KR, Wheelock MJ. 2005. Cadherin switching: Essential for behavioral but not morphological changes during an epitheliumto-mesenchyme transition. J Cell Sci 118(Pt 5): 873-887.
40. Malik AN, Vierbuchen T, Hemberg M, Rubin AA, Ling E, Couch CH, Stroud H, Spiegel I, Farh KK, Harmin DA, et al. 2014. Genome-wide identification and characterization of functional neuronal activity-dependent enhancers. Nat Neurosci 17: 1330-1339.
41. Martynoga B, Drechsel D, Guillemot F. 2012. Molecular control of neurogenesis: A view from the mammalian cerebral cortex. Cold Spring Harb Perspect Biol 4: A008359.
42. Massey PV, Bashir ZI. 2007. Long-term depression: multiple forms and implications for brain function. Trends Neurosci 30: 176-184.
43. Mehta A, Prabhakar M, Kumar P, Deshmukh R, Sharma PL. 2013. Excitotoxicity: bridge to various triggers in neurodegenerative disorders. Eur J Pharmacol 698: 6-18.
44. Milner B, Squire LR, Kandel ER. 1998. Cognitive neuroscience and the study of memory. Neuron 20: 445-468.
45. Mohn F, Weber M, Rebhan M, Roloff TC, Richter J, Stadler MB, Bibel M, Schübeler D. 2008. Lineage-specific polycomb targets and de novo DNA methylation define restriction and potential of neuronal progenitors. Mol Cell 30: 755-766.
46. Nestler EJ, Landsman D. 2001. Learning about addiction from the genome. Nature 409: 834-835.
47. Nord AS, Blow MJ, Attanasio C, Akiyama JA, Holt A, Hosseini R, Phouanenavong S, Plajzer-Frick I, Shoukry M, Afzal V, et al. 2013. Rapid and pervasive changes in genome-wide enhancer usage during mammalian development. Cell 155: 1521-1531.
48. Pokorska A, Vanhoutte P, Arnold FJ, Silvagno F, Hardingham GE, Bading H. 2003. Synaptic activity induces signalling to CREB without increasing global levels of cAMP in hippocampal neurons. J Neurochem 84: 447-452.
49. Pott S, Lieb JD. 2014. What are super-enhancers? Nat Genet 47: 8-12.
50. Rada-Iglesias A, Bajpai R, Swigut T, Brugmann SA, Flynn RA, Wysocka J. 2011. A unique chromatin signature uncovers early developmental enhancers in humans. Nature 470: 279-283.
51. Rogawski MA. 1992. The NMDA receptor, NMDA antagonists and epilepsy therapy. A status report. Drugs 44: 279-292.
52. Samee MA, Sinha S. 2014. Quantitative modeling of a gene's expression from its intergenic sequence. PLoS Comput Biol 10: E1003467.
53. Sanchez-Perez A, Llansola M, Cauli O, Felipo V. 2005. Modulation ofNMDA receptors in the cerebellum. II. Signaling pathways and physiological modulators regulatingNMDAreceptor function. Cerebellum 4: 162-170.
54. Sgambato-Faure V, Cenci MA. 2012. Glutamatergic mechanisms in the dyskinesias induced by pharmacological dopamine replacement and deep brain stimulation for the treatment of Parkinson's disease. Prog Neurobiol 96: 69-86.
55. Sharma K, Sheng HZ, Lettieri K, Li H, Karavanov A, Potter S, Westphal H, Pfaff SL. 1998. LIM homeodomain factors Lhx3 and Lhx4 assign subtype identities for motor neurons. Cell 95: 817-828.
56. Shaywitz AJ, Greenberg ME. 1999. CREB: A stimulus-induced transcription factor activated by a diverse array of extracellular signals. Annu Rev Biochem 68: 821-861.
57. Simon JM, Giresi PG, Davis IJ, Lieb JD. 2012. Using formaldehyde-assisted isolation of regulatory elements (FAIRE) to isolate active regulatory DNA. Nat Protoc 7: 256-267.
58. Snyder EM, Nong Y, Almeida CG, Paul S, Moran T, Choi EY, Nairn AC, Salter MW, Lombroso PJ, Gouras GK, et al. 2005. Regulation of NMDA receptor trafficking by amyloid-β. Nat Neurosci 8: 1051-1058.
59. Song L, Zhang Z, Grasfeder LL, Boyle AP, Giresi PG, Lee BK, Sheffield NC, Graf S, Huss M, Keefe D, et al. 2011. Open chromatin defined by DNaseI and FAIRE identifies regulatory elements that shape cell-type identity. Genome Res 21: 1757-1767.
60. Stadler MB, Murr R, Burger L, Ivanek R, Lienert F, Scholer A, van Nimwegen E, Wirbelauer C, Oakeley EJ, Gaidatzis D, et al. 2011. DNA-binding factors shape the mouse methylome at distal regulatory regions. Nature 480: 490-495.
61. Tanaka H, Nojima Y, Shoji W, Sato M, Nakayama R, Ohshima T, Okamoto H. 2011. Islet1 selectively promotes peripheral axon outgrowth in Rohon-Beard primary sensory neurons. Dev Dyn 240: 9-22.
62. Tao X, West AE, Chen WG, Corfas G, Greenberg ME. 2002. A calcium-responsive transcription factor, CaRF, that regulates neuronal activity-dependent expression of BDNF. Neuron 33: 383-395.
63. Thakurela S, Garding A, Jung J, Schübeler D, Burger L, Tiwari VK. 2013. Gene regulation and priming by topoisomerase IIα in embryonic stem cells. Nat Commun 4: 2478.
64. Thurman RE, Rynes E, Humbert R, Vierstra J, Maurano MT, Haugen E, Sheffield NC, Stergachis AB, Wang H, Vernot B, et al. 2012. The accessible chromatin landscape of the human genome. Nature 489: 75-82.
65. Tiwari VK, Burger L, Nikoletopoulou V, Deogracias R, Thakurela S, Wirbelauer C, Kaut J, Terranova R, Hoerner L, Mielke C, et al. 2012a. Target genes of Topoisomerase IIβ regulate neuronal survival and are defined by their chromatin state. Proc Natl Acad Sci 109: E934-E943.
66. Tiwari VK, Stadler MB, Wirbelauer C, Paro R, Schübeler D, Beisel C. 2012b. A chromatin-modifying function of JNK during stem cell differentiation. Nat Genet 44: 94-100.
67. Ulas J, Weihmuller FB, Brunner LC, Joyce JN, Marshall JF, Cotman CW. 1994. Selective increase of NMDA-sensitive glutamate binding in the striatum of Parkinson's disease, Alzheimer's disease, and mixed Parkinson's disease/Alzheimer's disease patients: An autoradiographic study. J Neurosci 14(11 Pt 1): 6317-6324.
68. Uwanogho D, Rex M, Cartwright EJ, Pearl G, Healy C, Scotting PJ, Sharpe PT. 1995. Embryonic expression of the chicken Sox2, Sox3 and Sox11 genes suggests an interactive role in neuronal development. Mech Dev 49: 23-36.
69. West AE, Chen WG, Dalva MB, Dolmetsch RE, Kornhauser JM, Shaywitz AJ, Takasu MA, Tao X, Greenberg ME. 2001. Calcium regulation of neuronal gene expression. Proc Natl Acad Sci 98: 11024-11031.
70. West AE, Griffith EC, Greenberg ME. 2002. Regulation of transcription factors by neuronal activity. Nat Rev Neurosci 3: 921-931.
71. Whyte WA, Orlando DA, Hnisz D, Abraham BJ, Lin CY, Kagey MH, Rahl PB, Lee TI, Young RA. 2013. Master transcription factors and mediator establish super-enhancers at key cell identity genes. Cell 153: 307-319.
72. Woolf CJ, Mannion RJ. 1999. Neuropathic pain: Aetiology, symptoms, mechanisms, and management. Lancet 353: 1959-1964.
73. Yao B, Jin P. 2014. Unlocking epigenetic codes in neurogenesis. Genes Dev 28: 1253-1271.
74. Young AB, Greenamyre JT, Hollingsworth Z, Albin R, D'Amato C, Shoulson I, Penney JB. 1988. NMDA receptor losses in putamen from patients with Huntington's disease. Science 241: 981-983.
75. Zhang SJ, Steijaert MN, Lau D, Schütz G, Delucinge-Vivier C, Descombes P, Bading H. 2007. Decoding NMDA receptor signaling: identification of genomic programs specifying neuronal survival and death. Neuron 53: 549-562.
76. Zheng S, Eacker SM, Hong SJ, Gronostajski RM, Dawson TM, Dawson VL. 2010. NMDA-induced neuronal survival is mediated through nuclear factor I-A in mice. J Clin Invest 120: 2446-2456.